


**Figure S1. Schematic representation of animal treatment.**



**Figure S2. MEK inhibitors promote cell death by 5-ALA-PDT in cancer cell lines *in vitro*.** 4T1

and DLD-1 cells were treated with or without MEK inhibitors U0126 (20  $\mu$ M) or selumetinib (20  $\mu$ M) for 20 h and then with 5-ALA (5 mM) for 4 h followed by irradiation. Mean  $\pm$  SD of % Cell viability at 24 h after 5-ALA-PDT compared to control (DMSO, black bar) from three independent experiments is shown. \* $p$ <0.01 by one-way ANOVA with Turkey's posthoc test.

<b>5-ALA (mM)</b>	<b>U0126 (<math>\mu</math>M)</b>	<b>CI</b>
0.5	2.5	<b>0.60</b>
0.5	5.0	<b>0.49</b>
0.5	10.0	<b>0.28</b>
0.5	20.0	<b>0.12</b>
5.0	2.5	<b>0.90</b>
5.0	5.0	<b>0.83</b>
5.0	10.0	<b>0.62</b>
5.0	20.0	<b>0.06</b>

**Supplementary Table 1.** Chou and Talalay analysis of the interaction between 5-ALA PDT and MEK inhibitor U0126. The table shows the combination indices (CI) for the treatment combinations shown in Figure 3.